Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — VA Clarifies That Veterans Working in Cannabis Industry Can Apply for Home Loans

Although dozens of states have now legalized medical cannabis and studies have found that cannabis can be quite effective at treating issues such as and post-traumatic stress disorder, veterans often struggle to access cannabis. Furthermore, military veterans who work in state-legal cannabis industries often lack the benefits and protections from the U.S. Department of Veteran Affairs that veterans outside the industry enjoy because cannabis is still illegal at the federal level.

In a move that is sure to be met with praise from veterans, cannabis reform activists and industry stakeholders, the VA has clarified that veterans who work in the cannabis industry are eligible for home loans. However, the department noted that while vets who now draw their income from state-legal cannabis businesses can apply for home loans, some prospective lenders may not be willing to issue them loans. Such lenders see the instability caused by marijuana’s federal status as a Schedule I drug and they may not want to run the risk of veterans in the industry defaulting on their loans.

Even so, the VA stressed in a recent memo that since hemp is federally legal under the 2018 Farm Bill, veterans who work with hemp and hemp products should not be discriminated against when applying for home loans via the department’s benefits program. Ideally, this should cover veterans who work in the CBD industry as most of the cannabidiol on the market is derived from hemp, a nonpsychoactive type of cannabis.

The VA stressed that veterans who earn a living in the marijuana industry cannot be barred from obtaining a certificate of eligibility. This is a document that confirms a veteran’s eligibility for a Veteran Affair’s guaranteed loan.

The memo did note that the current federal ban on marijuana may make it difficult for lenders to establish if the income derived from cannabis businesses is stable and reliable enough to pay a home loan. As a result, the memo stated, such lenders may be uncomfortable relying on marijuana-derived income when they underwrite VA-guaranteed loans.

On the other hand, veterans who are involved in the retail sale of hemp fabric and cannabis-related products that are federally compliant would not run into the same issues when seeking home loans.

This is not the first time the VA has raised the issue of home-loan eligibility for veterans working in the cannabis industry. For example, in 2020, the department issued a report stating that drawing income from state-legal cannabis did not render a veteran ineligible for VA benefits.

As these inconsistencies are addressed one by one, more people will reap the benefits of being in jurisdictions where entities such as Flora Growth Corp. (NASDAQ: FLGC) are allowed to operate and make a difference in the community.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California Wants Standardized THC Testing to Prevent Lab Shopping

America’s cannabis industry may be insanely lucrative, but it desperately lacks standardized regulations. Each state with a legal cannabis market has its own marijuana policies, leading to a patchwork of regulations across the country. And even within individual states, there tends to be little standardized regulation. In California, which is home to the largest cannabis market in the country, this manifests as THC “laboratory shopping.”

This term refers to cannabis companies that shop around for laboratories which are more likely to show that their products have higher THC concentrations to make them more popular. State cannabis regulators in California are now looking for public input on proposed rules that would finally create standardized marijuana testing techniques.

Regulators say that they are aware the insane demand for cannabis may cause some businesses to shop around for labs that use testing methodologies that are more likely to show higher concentrations of THC. Ideally, standardized testing methods would ensure different testing facilities use the same standard methodologies when running tests on cannabis products.

As such, the California Department of Cannabis Control (DCC) has announced that it is beginning the rulemaking process that would result in the development of standardized testing practices for every licensed laboratory in the state. Speaking in a press release, DCC director Nicole Elliot said that since individual labs leverage different testing methods, they may produce inaccurate data and inconsistent results on the cannabinoid content in cannabis products.

Elliot said that the department is working to provide standard testing procedures to ensure there is integrity in the cannabis market as well as accurate data on cannabinoid and terpene content for the consumers; these guidelines would undoubtedly boost confidence among industry stakeholders. As per the proposed Senate Bill 544, the DCC will be required to establish standardized methods for testing cannabinoids by the end of this year.

By requiring that cannabis testing laboratories only use testing standards provided by the DCC, Elliot says the department will protect public health by providing consumers with consistently accurate information about the contents of the cannabis products they consume. Aside from testing for cannabinoid and terpene levels, these tests are also crucial to ensuring that cannabis products on the shelves aren’t contaminated with pesticides, mold, heavy metals and residual solvents.

The DCC will accept public comments on the proposed cannabis testing regulations until Aug. 2, 2022. Furthermore, the department will hold a public hearing for individuals who would like to offer in-person testimonies on Aug. 1, 2022.

The efforts being made to close any regulatory loopholes that some sector actors have been exploiting will level the field for all licensed companies, including American Cannabis Partners, so that all play by the same rules with no one company enjoying an unfair market advantage.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Health Canada Remains Quiet on Timeline for Reviewing Marijuana Law

More than eight months after the Canadian government was supposed to begin a review of Canada’s 2018 adult-use legalization law, authorities have yet to begin the process. Additionally, Health Canada, the department in charge of the country’s national health policy, still hasn’t provided a timeline for reviewing the recreational cannabis law.

This delay has hindered the development of much-needed legislative reforms for the recreational cannabis industry, one industry executive believes. According to Aurora Cannabis senior vice president of global government relations Rick Savone, the legislative review needs to cover a lot before the industry can get the regulations it desperately needs.

However, he says that the government’s inaction means that precious little is getting done from a legislative or regulatory perspective. Savone also acts as the chairman of the Cannabis Council of Canada. The report, which was slated to start by October 2021, should have begun three years after Canada legalized adult-use marijuana.

The Cannabis Act that legalized recreational cannabis in Canada contained a provision requiring a review of the country’s legalization law three years after the law was enacted. When asked if the review had begun earlier this year, Health Canada spokeswoman Tammy Jarbeau declined to offer a specific timeline and stated that preparations for the review were underway.

More than four months later, the department still hasn’t provided a public timeline for the review process, leaving industry players waiting with bated breath. Savone says that most industry players are eagerly waiting to see how the statutory review goes before they can make the moves they need to make. In the meantime, however, he says that their competitors, especially those on the global scale, are steadily gaining market positions.

Stakeholders in Canada’s nascent recreational cannabis industry are anxious to cover issues such as government regulatory fees, potency limits for cannabis-infused edibles, excise taxes, and limitations on advertising and marketing once the review commences. Although the Cannabis Act doesn’t cover all of these issues, stakeholders say those issues still deserve to be addressed.

Fortunately, industry insiders will have a chance to discuss the issues in an upcoming cannabis roundtable that will bring together government officials as well as industry insiders to discuss key issues.

Although Health Canada hasn’t said why it hasn’t started the review, industry sources say there are several reasons behind this delay, including the coronavirus pandemic and the September 2021 snap election followed by the appointment of a new health minister.

The delays in Canada show that it isn’t only American-based companies such as Advanced Container Technologies Inc. (OTC: ACTX), which are being held back by the lack of progress in bringing national policies in line with the available science and the wishes of the people.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Connecticut Company Leverages DEA License to Supply Marijuana for Yale Research

CT Pharma, a Connecticut-based medical marijuana production and research company, made history in 2019 when the U.S. Drug Enforcement Administration allowed it to grow marijuana for FDA-approved research. It became the first state-licensed cannabis company that could legally provide cannabis for studies funded by the federal government, breaking the University of Mississippi’s monopoly on cultivating research-grade cannabis.

The university had been the only federally approved supplier of cannabis for years. Still, researchers regularly complained that the cannabis produced by the facility was low-grade and compromised the results of their studies.

In a move that is sure to be approved by the cannabis research community, CT Pharma is now partnering with Yale University to produce cannabis for research on whether cannabis-derived tablets can be effective treatments against pain and stress. Researchers from Yale University will use cannabis flower cultivated in CT Pharma’s Rocky Hill, Connecticut facility. The company’s president, Rino Ferrarese, said that this federally funded study will leverage plant material cultivated within a state-level medical program, making it unique compared to other cannabis studies.

Ferrarese is also the executive vice president of the north region for Verano Holdings, an Illinois-based company that recently acquired CT Pharma. In early 2020, he predicted that this study would end in the creation of an FDA-approved, cannabis-derived tablet that could be on the market as soon as 2025. He stated that the federal agency had finally “opened up” and no longer took decades to approve new therapies.

Ferrarese believes that the FDA is interested in approving more effective treatment therapies sooner but noted that both patients and the industry as a whole would benefit from being slow and meticulous.

Even so, obtaining FDA approval for the study was far from easy. According to Ferrarese, the FDA was particularly interested in seeing if CT Pharma’s cannabis was cultivated, extracted, manufactured and packaged under Good Manufacturing Practice Standards. The agency requested the cleaning logs, facility layout and cultivation batch records. Furthermore, CT Pharma was required to provide potency, microbiology and stability tests to prove that the cannabis biomass was not contaminated.

All in all, the agency asked CT Pharma for “reams and reams of information,” Ferrarese said, including analytical reports, master batch records, facility control documentation and training records for all facility staff.

Yale University of Medicine professor Ranjita Sinha is in charge of the study and has already made some headway in the pain-management study. Her team discovered that a 40 mg CBD tablet with a low-THC dose and a 100 mg CBD tablet with little THC are reasonably efficient at alleviating pain.

As more research entities gain access to research-grade cannabis, which is representative of the marijuana products that consumers buy from state-legal sources, the public is bound to obtain a deeper understanding of how the products of regulated companies such as Prime Harvest Inc. can impact their health for the better and any drawbacks to such cannabis use.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Benefiting from ‘Snowballing’ Fresh Frozen Cannabis Market

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, recently announced the first transaction under its contract with Cannabis Global Inc. (OTC: CBGL). “The transaction calls for Sugarmade to produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines and will distribute to the California marketplace. Sugarmade and Cannabis Global have signed a prebooked, fixed-price contract in the amount of $700,000…” a recent article reads. This comes as a growing number of cannabis consumers are choosing Fresh Frozen cannabis, which is flash frozen immediately after harvest instead of undergoing the traditional treatment of drying and curing, as they seek naturally produced cannabis products full of plant terpenes and flavors. Cannabis Global CEO Arman Tabatabaei is quoted saying, “The market for Fresh Frozen cannabis is snowballing. Thus, we believe it is the place to be for the 2022 cultivation season. We plan to process a large portion of the 25,000 pounds of ultra-premium cannabis at our Lynwood, California, laboratory, creating premium solventless extracts for sale into the market and for use in our own manufactured products, thus creating vertical integration to reduce our costs of goods sold.”

To view the full article, visit https://cnw.fm/OBbxH

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, Lemon Glow and Budcars. For more information, please visit www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://cnw.fm/SGMD

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh patent family and is related to tetrahydrocannabinol (“THC”). The company also noted that it has patents granted or patent applications progressing in countries around the world. Lexaria also reported that the company had submitted its briefing book to the US Food and Drug Administration (“FDA”), which was required for the upcoming pre-Investigational New Drug (“IND”) meeting that the company has requested.  

To view the full press release, visit https://cnw.fm/iux4X

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted, plus a 26th patent allowed, as well as an estimated 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lehua Brands, CA State Fair Cannabis Awards to Offer Adult Fairgoers Opportunity to Experience Special Edition TerpTonic Beverages

Lehua Brands is serving as the official beverage of the CA State Fair Cannabis Awards and today announced the special edition TerpTonic beverages in collaboration with four of California’s most acclaimed cannabis cultivators. According to the announcement, the special edition TerpTonic beverages and slushies will be available for purchase (quantities may be limited) at the Lehua Brands booth (#13) within the CA Cannabis Exhibit at the CA State Fair in Expo Center Building One. The cultivators and their award-winning strains include two Golden Bear “Best of California” winners, Esensia Gardens (Buddha’s Hand) and Greenshock Farms (Passion Orange Guava), as well as two Gold Medal winners, Booney Acres (Gelonade) and Emerald Spirit Botanicals (Pink Boost Goddess). “The CA State Fair Cannabis Awards is delighted to offer adult fairgoers the opportunity to experience these exceptional flower strains in a truly novel format,” said Cultivar Brands CEO James Leitz. “Lehua Brand’s beverages and slushies deliver the unique flavors and aromas of the plant, with enhanced CBD, but no THC. Lehua’s TerpTonics offer an ideal means to educate the consumer by experiencing the natural herbal complexity of the cannabis plant.”

To view the full press release, visit https://cnw.fm/ZhTD9

About Lehua Brands Ltd.

Based in King City, Monterey County, Lehua is a licensed manufacturer and distributor of award-winning cannabis products. These include Olala craft sodas, VOILA! sparkling water, TerpTonic single-strain tonics, Herbology, HAKU Blue and HAKU Red vape cartridges, and soon-to-be-released TIKI Blast 100 mg high-potency elixir. PhenoTech Inc., a wholly owned technology company, specializes in the manufacture and sale of ingredients including, but not limited to, extracts and water-soluble emulsions in exclusive partnership with Cirona Labs. For more information about Lehua, visit www.LehuaBrands.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Senators Express Disappointment with President Biden’s Failure to Enact Marijuana Reforms

President Joseph Biden based part of his campaign on marijuana reform, stating that he would pursue marijuana decriminalization and the expungement of prior cannabis-related offenses. However, one-and-a-half years after he took office, the Biden administration has barely taken any action to keep the president’s marijuana promises. This inaction has been met with criticism and disappointment from drug reform activists and lawmakers.

Six U.S. senators recently renewed their call for the president to fulfill his cannabis promises, specifically de-scheduling cannabis and granting mass pardons to people currently incarcerated for cannabis offenses. Furthermore, they said that the Justice Department’s response to a letter the lawmakers sent in October 2021 was “extraordinarily disappointing.”

Sens Bernie Sanders, Elizabeth Warren, Cory Booker, Ed Markley, Kirsten Gillibrand and Ed Markey were signatories to the new letter sent to the president, Human Services (HHS) secretary Xavier Becerra, and Attorney General Merrick Garland.

They requested that the attorney general remove marijuana from the Controlled Substances Act (CSA) and that \ Biden issue mass pardons to people who were convicted for nonviolent federal cannabis offences. According to the senators, it took the DOJ a whopping six months to reply to the letter the   y sent last October asking the attorney general to use his power to independently begin the process of removing cannabis from the CSA.

The ‘half-page response’ they received this April was extraordinarily disappointing, the senators wrote in the new letter. As per the April 2022 letter, the DOJ stated that the HHS still hadn’t determined that cannabis could be a safe and effective treatment option, hence its inaction. But the senators argued in their most recent letter that this ignored the fact that the DOJ and the Drug Enforcement Administration (DEA) had the power to start the de-scheduling process without the HHS’s input.

They say that the Controlled Substances Act empowers Attorney General Garland to request a scientific review from the HHS. Even if Human Services recommends that cannabis remain a Schedule I controlled substance or move to a lower schedule, the attorney general could still start the process of removing cannabis from the CSA. As such, the DOJ does not need a determination from the HHS to begin the de-scheduling process, the senators said, and research has already proven that cannabis does have medical benefits.

A coalition of senators, including Senators Warren and Markey sent Biden a letter in November 2021 urging him to grant mass clemency to people with federal cannabis convictions. However, the administration still hasn’t responded to the letter to date. The recent letter stated that while Biden’s efforts to grant pardons to 78 people were commendable, his administration needed to do much more to handle the situation

The entire cannabis industry, including entities such as Flora Growth Corp. (NASDAQ: FLGC), is also wondering when the federal government will ever wake up and recognize that science has proven that marijuana does possess medical benefits and that many patients see it as a godsend.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DC Mayor Enacts Measure Allowing Patients to Self-Certify as Medical Cannabis Patients

Dozens of states in the United States have now legalized medical cannabis use. In most of these territories, qualifying patients have to receive a recommendation from their doctor before accessing medical marijuana.

In Washington, DC, however, patients will now be able to certify themselves as medical cannabis patients without a physician’s recommendation after the mayor recently signed emergency legislation into law. The district council approved the measure unanimously last week in a 13 to 0 vote.

The emergency bill effectively allows the council to work around a congressional rider that forbids the district from using federal dollars to launch a recreational cannabis market. Councilmembers Mary Cheh and Kenyan McDuffie first introduced the bill.

Mayor Muriel Bowser said that the legislation would build on efforts by Washington lawmakers to create a patient-centric medical cannabis program. She stated that allowing more patients to access medical marijuana when needed and leveling the playing field for licensed medical marijuana sellers will protect the residents, provide opportunities for local businesses and provide much-needed clarity.

Bowser applauded the district council for approving the legislation, calling it an innovative solution to the complex issues that affect DC’s medical cannabis sector.  Furthermore, she added that she was looking forward to working with the council and the Alcoholic Beverage Regulation Administration (ABRA) on future comprehensive and permanent medical cannabis reform.

Earlier district council chair Phil Mendelson introduced a similar bill that would have facilitated the self-certification process, but DC lawmakers voted it down in April. The bill had received criticism because of provisions that would have given law enforcement leeway to crack down on unlicensed businesses that were taking advantage of current policies to “gift” cannabis to customers who purchased unrelated services and gifts.

Faced with claims that these provisions could further the harms caused by the war on drugs while benefiting existing industry interests, Mendelson said that the bill said nothing about criminal penalties for such establishments.

He argued that such businesses weren’t just a gray market, they are illegal and are eroding the customer bases of licensed medical marijuana businesses. Mendelson said that his measure would make it easier for licensed medical cannabis businesses to maintain their customer base. However, the law failed to advance.

The emergency legislation that was recently signed into law does not contain these enforcement provisions. However, it notes that customers often have little or no barriers to accessing cannabis from “gray” market suppliers.

The growing frustration about the hindrances to the cannabis industry originating from the federal government’s stance isn’t restricted to sector such as Cannabis Strategic Ventures Inc. (OTC: NUGS). Even jurisdictions such as Washington, DC, are reaching the limit of their patience and have started finding workarounds to the outdated federal restrictions as exemplified by the law discussed above.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the pending start of its upcoming human nicotine study NIC-H22-1. Through the study, Lexaria expects to evidence that processing purified nicotine with its patented drug delivery technology, DehydraTECH(TM), leads to enhanced oral-tissue absorption and reduced negative experiences. NIC-H22-1, a minimum 36-person human pharmacokinetic (“PK”) randomized, double blinded, cross-over study, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. The primary objective of the study is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives include extensive subjective evaluations related to throat burn, user experience and more. Nicotine test article ingredient manufacturing and DehydraTECH processing have been completed, and the third-party pouch manufacturing company has received those processed materials for filling and packaging. Independent Review Board approval and subsequent human dosing will be the next two major steps in the study.

To view the full press release, visit https://cnw.fm/lxZ3F

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.